Navigation Links
Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
Date:8/21/2008

Research Study Will Explore Therapeutic Cellular Platform Utilizing Cord Blood and Menstrual Blood Derived Stem Cells in the Formation of Emergent

Vascular Structures

OLDSMAR, Fla., Aug. 21 /PRNewswire-FirstCall/ -- Cryo-Cell International, Inc. and EndGenitor Technologies, Inc. are pleased to announce a new research collaboration to co-develop a combined cellular platform therapeutic for rapidly forming vasculature in injured tissues. Currently, intense research into the mechanisms of initiation of angiogenesis and the repair of damaged vasculature is underway in order to identify the participating molecular and cellular components involved. Greater understanding of this highly-complex process is paving the way to identify novel potential therapeutics for treating cancer and cardiovascular disease.

The research will focus on the utilization of cord blood and menstrual blood derived cells, known as ECFCs(R) and MenSCs, respectively. ECFCs(R) are cord blood-derived endothelial colony-forming cells. ECFCs(R) are currently in pre-clinical development by EndGenitor for cardiovascular and other therapeutic applications. MenSCs, which were discovered and developed by Cryo-Cell, are primitive mesenchymal progenitor cells found in menstrual blood and are easily retrievable without invasive techniques.

"We think the project has significant potential, as both ECFCs(R) and MenSCs contribute to angiogenesis in vivo, which underscores the importance of further study into the potential synergy of these cells in the formation of vasculature," said Dr. Julie Allickson, Vice President of Laboratory Operations and Research and Development at Cryo-Cell, which developed and maintains proprietary intellectual property (IP) on MenSCs.

"EndGenitor is extremely pleased to have the opportunity to partner with Cryo-Cell International in the development of its regenerative medicine product lines. The synergy resulting from Cryo-C
'/>"/>

SOURCE Cryo-Cell International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cryo-Cell International, Inc. Reports Second Quarter 2008 Results
2. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
3. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
4. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
5. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
6. Yongye Biotechnology International Announces Second Quarter Results
7. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
8. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
9. Yongye Biotechnology International Retains CCG Investor Relations
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. SpineMark Appoints Dr. Rudolf Bertagnoli Chairman of International Medical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... 2015  StemProtein LLC, a leading manufacturer of ... Stemedica Cell Technologies Inc., announced today that it ... of StemProtein. Silberg will help advance the Company,s ... Cell Factors (SCFs), a significant consumer opportunity. ... and biopharmaceutical industries with substantial executive level experience ...
(Date:9/3/2015)... CA (PRWEB) , ... September 03, 2015 , ... ... and additive manufacturing on Sept. 17, 2015 at 9am PST. The webinar will focus ... application. More popularly known as 3D printing, additive manufacturing is a broad term that ...
(Date:9/3/2015)... ... ... If you plan to attend the 27th annual Tradeline College and ... sign up for the tour of Framingham State University's newest addition to Hemenway Hall ... the (8) chemistry teaching labs that are exclusively utilizing (49) filtered fume hoods ...
(Date:9/2/2015)... Sept. 2, 2015 Research and ... addition of Jain PharmaBiotech,s new report ... their offering. An increasing ... biotechnology industries is anticipated. Nanotechnology will be ... - from formulations for optimal delivery to ...
Breaking Biology Technology:StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 2StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 3Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 2Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 3Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 4Erlab Invites You to Tour the Largest Installation of Filtered Fume Hoods in the World 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3
... Point of Preventing Bacterial Colonization with ... Leader, VANCOUVER, March 18 /PRNewswire-FirstCall/ - ... ANP), a global specialty pharmaceutical and,medical device ... from its 960,patient clinical trial comparing its ...
... RainDance Technologies, Inc.,a developer of NanoReactor ... Stephen E. Becker as Vice President,Commercial Officer, ... responsible for continuing the growth of the,company,s ... launch of its first,life science offering," said ...
... AAAAI 64th Annual Meeting also show that C1-INH is ... HAE attacks across all body sites, PHILADELPHIA, March ... effective therapy that rapidly relieves acute,abdominal and facial swelling ... serious genetic disorder, according to data,presented today at the ...
Cached Biology Technology:960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 2960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 3960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 4960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 5960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 6960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 7RainDance Appoints Becker Chief Commercial Officer 2RainDance Appoints Becker Chief Commercial Officer 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 2C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 4
(Date:8/5/2015)... ALBANY, New York , August 5, 2015 /PRNewswire/ ... new market report titled "Facial Recognition Market - Global ... - 2022", the global market for facial recognition is ... market is driven by increased demand for surveillance systems ... to the rising number of crimes and terrorist activities ...
(Date:8/4/2015)... -- AMRI (NASDAQ: AMRI ) today reported financial and operating results ... , Second quarter contract revenue of $ 85.2 ... Adjusted contract margins of 26 % , ... decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, with ...
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... redundant portions of the fruit fly genome may not ... from a Princeton-led team of researchers suggest that repeated ... normal development under less-than-ideal growth conditions by making sure ... appropriate times. If similar regions are found in humans, ...
... estimated to afflict as many as 12 million people worldwide ... vulnerable to compounds developed to treat cancer and other disorders, ... have found. Scientists searched the genome of the parasite ... of TOR kinases, proteins that are linked to cell growth ...
... SPOKANE, Wash.Washington State University researchers have discovered a way to ... for slowing and even stopping the growth of tumors. "Hopefully, ... Weihang Chai, an assistant professor in the WSU School of ... "Basically, you make the cancer cell go from immortal to ...
Cached Biology News:Redundant genetic instructions in 'junk DNA' support healthy development 2Redundant genetic instructions in 'junk DNA' support healthy development 3Redundant genetic instructions in 'junk DNA' support healthy development 4Cancer drugs may help stop major parasite 2
... Ribonuclease Inhibitor is a potent ... such as RNase A. Like ... Ribonuclease Inhibitor is an acidic ... ~52 kDa. RNaseOUT inhibits RNase ...
... Inhibitors have broad spectrum RNase inhibitory properties, ... the neutral type (1). The 50kDa protein ... to RNases in a 1:1 ratio. The ... Ribonuclease Inhibitor to RNase (e.g., RNase A) ...
UGT1A7 (E-15)...
... corresponding to the third cytoplasmic loop of ... to KLH. The immunizing peptide has 79% ... Physical form: Solution in phosphate buffered ... Titertest method: IHC (p). Titertest ...
Biology Products: